Novem Group Buys Shares of 1,038 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Novem Group purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,038 shares of the biopharmaceutical company’s stock, valued at approximately $739,000.

A number of other hedge funds have also modified their holdings of REGN. Merit Financial Group LLC grew its stake in Regeneron Pharmaceuticals by 8.9% in the fourth quarter. Merit Financial Group LLC now owns 868 shares of the biopharmaceutical company’s stock valued at $618,000 after purchasing an additional 71 shares in the last quarter. Diversify Advisory Services LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $234,000. Crossmark Global Holdings Inc. grew its stake in shares of Regeneron Pharmaceuticals by 3.6% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,654 shares of the biopharmaceutical company’s stock valued at $1,890,000 after buying an additional 92 shares in the last quarter. Aspiriant LLC increased its holdings in Regeneron Pharmaceuticals by 14.5% in the fourth quarter. Aspiriant LLC now owns 387 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 49 shares during the last quarter. Finally, Atomi Financial Group Inc. raised its position in Regeneron Pharmaceuticals by 7.0% during the fourth quarter. Atomi Financial Group Inc. now owns 615 shares of the biopharmaceutical company’s stock valued at $438,000 after acquiring an additional 40 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $604.62 on Thursday. The company’s fifty day moving average is $595.54 and its two-hundred day moving average is $679.20. The firm has a market capitalization of $65.28 billion, a price-to-earnings ratio of 15.79, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 52-week low of $520.50 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business earned $9.55 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. The Goldman Sachs Group reduced their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. UBS Group decreased their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating on the stock in a report on Wednesday, April 30th. Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price target for the company. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $890.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.